Nanotechonlogy has attracted intense interest in several areas, including pharmaceuticals. Among the various nanotechnology products available, the pharmaceutical nanoparticle systems have been highlighted by driving drugs into sites of action and acting as drug carriers, increasing the therapeutic efficacy. These characteristics are fundamental to the treatment of many diseases, including cancer. Despite the numerous advantages of anticancer nanocapsules, their pharmacological and toxicological parameters have not been fully comprehended. In this context, this study aims to evaluate the anti-carcinogenic activity and possible toxic effects of eugenol nanocapsules and of eugenol solution. Male C57BL6 mice will be i.v. treated with fluorophore (Rhodamine B)-labeled eugenol nanocapsules or with eugenol solution. The nanocapsules distribution in the microcirculation in the liver or in the B16F10-induced melanoma tumor mass in the subcutaneous dorsal tissue; leukocyte-endothelial interactions; formation of thrombus and hemorrhagic areas, and therapeutic efficacy by measuring the kinetics of tumor formation in the dorsal subcutaneous tissue will be measured by intravital microscopy. Additionally, SK-Mel-28 human melanoma and HUVEC human endothelium cell lines will in vitro treat with the compounds to assess cell viability, cell proliferation, cell cycle and DNA fragmentation by flow cytometry assay; cell adhesion and production of nitric oxide will be quantified by spectrophotometry assay; cell migration in Matrigel® and tissue morphology in hematoxylin and eosin stained tissues will be monitored by optical microscopy. Data obtained in this study may indicate in vitro and in vivo studies to evaluate the therapeutic and toxic action of anti-cancer nanocapsules, and they may contribute to the comprehension of toxic actions of eugenol in the microcirculatory network. Additionally, this project will contribute to the establishment of protocols for study nanotechnology by intravital microscopy, which has not been employed in Brazil, and consolidate the collaboration with Drs Silvia Guterres and Adriana Polhmann´s groups, from the Federal University of Rio Grande do Sul, and specialized in the production of nanocompounds for pharmaceutical application.
News published in Agência FAPESP Newsletter about the scholarship: